Compare

Immunocore Holdings plc vs Krystal Biotech, Inc. vs Tarsus Pharmaceuticals, Inc. vs Twist Bioscience Corp

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearImmunocore Holdings plc
IMCR
Krystal Biotech, Inc.
KRYS
Tarsus Pharmaceuticals, Inc.
TARS
Twist Bioscience Corp
TWST
Year ended2025-12-312025-12-312025-12-312026-09-30
Revenue$400.02M$389.13M$451.36M$459.43M
Revenue growth (YoY)+29.0%+33.9%+146.7%+22.0%
Gross marginn/an/an/a52.4% (computed)
Operating margin-11.3%41.5%-15.7%-30.4%
Net margin-8.9%52.6%-14.7%-28.3%
Net income-$35.51M$204.83M-$66.42M-$130.20M
EPS (Diluted)-$0.71$6.84-$1.59-$2.08
Operating cash flow-$10.71M$200.87M-$12.45M-$41.43M
Free cash flow-$15.05M$188.91M-$22.31M-$89.01M
Cash & equivalents$467.71M$496.30M$183.64M$533.99M
Total assets$1.07B$1.33B$562.16M$1.12B
Total liabilities$686.24M$114.23M$218.73M$233.79M
Shareholders' equity$381.03M$1.22B$343.43M$888.02M
Return on year-end equity-9.3%16.8%-19.3%-14.7%
Shares outstanding50.69M29.19M42.55M67.81M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearImmunocore Holdings plcKrystal Biotech, Inc.Tarsus Pharmaceuticals, Inc.Twist Bioscience Corp
Latest$400.02M
Ended 2025-12-31
$389.13M
Ended 2025-12-31
$451.36M
Ended 2025-12-31
$459.43M
Ended 2026-09-30
1 year earlier$310.20M
Ended 2024-12-31
$290.51M
Ended 2024-12-31
$182.95M
Ended 2024-12-31
$376.57M
Ended 2025-09-30
2 years earlier$249.43M
Ended 2023-12-31
$50.70M
Ended 2023-12-31
$17.45M
Ended 2023-12-31
$312.97M
Ended 2024-09-30
3 years earlier$174.36M
Ended 2022-12-31
$0
Ended 2022-12-31
$25.82M
Ended 2022-12-31
$245.11M
Ended 2023-09-30
4 years earlier$36.48M
Ended 2021-12-31
$0
Ended 2021-12-31
$57.03M
Ended 2021-12-31
$203.56M
Ended 2022-09-30